http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3948301-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_523523e4857f980c860a0d49e77ed0ec |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 |
| filingDate | 2020-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eaa4fc5e8996f73848a4f822cf17893d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79521af7597e5eb647f5f892369be74b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcb5e0a3c1c46c99f014b327d8eae883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_152c5f1594292612f093ff01637fa257 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29cd306cc2ed2952d3cdd3dfe9a2c97c |
| publicationDate | 2022-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3948301-A1 |
| titleOfInvention | Prescription of remote patient management based on biomarkers |
| abstract | The invention relates to a method for determining whether a subject diagnosed with a cardiovascular disease should be prescribed a remote patient management, the method comprising measuring particular biomarkers in a sample from said patient. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a remote patient management for a patient diagnosed with a cardiovascular disease, comprising providing at least one sample of a patient, determining a level of at least one biomarker selected from the group consisting of pro ADM, pro BNP and pro ANP or fragment(s) and comparing said level of the at least one biomarker to one or more reference values, wherein said level is indicative of prescribing or not prescribing a remote patient management for said patient. In some embodiments a low benefit level of the at least one biomarker is indicative of not prescribing a remote patient management, whereas in some embodiments a high benefit level of the at least one biomarker is indicative of prescribing a remote patient management. In some embodiments the cardiovascular disease is heart failure, in particular a chronic heart failure that has led to a hospitalization within the last 12 months. |
| priorityDate | 2019-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 979.